IntelliCell BioSciences (SVFC) Adds Raymond Hill To Board Of Directors

IntelliCell BioSciences (SVFC) Adds Raymond Hill To Board Of Directors

NEW YORK, NY--(Marketwired - August 21, 2014) - IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB: SVFC), a regenerative medicine company utilizing adult autologous stromal vascular cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it has added Mr. Raymond Hill to its Board of Directors.

Mr. Hill has held a number of senior executive roles in the pharmaceutical industry, including President of InVentiv Clinical, CEO and member of the Board of Directors of PPD, and President of IMS Consulting Group. Earlier on in his career, Mr. Hill was a partner at A.T. Kearney and a consultant at Booz Allen & Hamilton.

IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a significant addition to the Board of Directors as Mr. Hill brings substantial experience in the field of FDA clinical trials. Mr. Hill is a valuable asset to the company, especially as IntelliCell is embarking on FDA IND clinical claim studies for Osteoarthritis with Dr. James Andrews as well as exploring clinical studies for Autism and ALS."

About IntelliCell Biosciences

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous stromal vascular fraction cells (SVFCs) derived from the blood vessels in the adult adipose tissue. IntelliCell BioSciences has developed its own patented technology and protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell is also developing technology-licensing agreements with technology developers, universities, and international business entities.

Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "will reach," "will change," "will soon," "should," "could," "would," "may," "can" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission. 


IntelliCell BioSciences, Inc.
Investor Relations
Anna Rhodes
Email Contact